Ironwood Pharmaceuticals (IRWD) : Tuesdays money flow indicated an uptick to downtick ratio was at 1.42. The total value of inflow transactions on upticks was $2.25 million, whereas, the total value of outflow trades on downticks was $1.58 million. The total money flow was $0.67 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.84 million. The total value of the trades done on upticks was $1.16 million. Downticks saw transactions worth $0.32 million. The total uptick to downtick ratio stood at 3.59, mildly in favor of the bulls. Ironwood Pharmaceuticals (IRWD) was trading with a -2.95% change over previous days close. It fell $0.39 during the day and reached $12.83. The stock was -4.04% compared to the previous weeks close.
The company Insiders own 7.17% of Ironwood Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.38% . Institutional Investors own 97.06% of Ironwood Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of 8.25%. In an insider trading activity, The Securities and Exchange Commission has divulged that Olanoff Lawrence S, director of Ironwood Pharmaceuticals Inc, had unloaded 2,200 shares at an average price of $12.92 in a transaction dated on June 3, 2016. The total value of the transaction was worth $28,424.
Ironwood Pharmaceuticals, Inc. has lost 2.3% in the last five trading days and dropped 0.85% in the last 4 weeks. Ironwood Pharmaceuticals, Inc. is up 11.73% in the last 3-month period. Year-to-Date the stock performance stands at 10.09%.
Ironwood Pharmaceuticals (NASDAQ:IRWD): On Tuesdays trading session , Opening price of the stock was $13.29 with an intraday high of $13.34. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $12.73. However, the stock managed to close at $12.76, a loss of 3.48% for the day. On the previous day, the stock had closed at $13.22. The total traded volume of the day was 2,483,151 shares.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.